Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
The DNA Assembly Scientist will be responsible for advancing the company’s science by designing and building the next generation of therapeutic tools and reagents. This individual will join a dynamic, rapidly growing, and highly collaborative team that combines significant biologic drug discovery experience with pioneering discoveries driving a novel biological platform.
- Design, build and modify potential therapeutic reagents using advance molecular biology techniques.
- Engage deeply with our therapeutic discovery teams to assist in the design process
- Assemble potential therapeutic reagents into plasmids or other vectors by performing molecular cloning protocols including Gibson assembly, Golden Gate reactions and site directed mutagenesis etc.
- Help junior team members in troubleshooting their experiments.
- Perform molecular biology assays and techniques, including PCR, gel electrophoresis, plasmid minipreps etc.
- Establish in-house DNA sequencing capabilities by NGS.
- Prepare nucleic acids for high-throughput quantitative PCR and sequencing
- Perform mammalian cell culture, cloning, transformation.
- Participate and present data in project team meetings.
- PhD (preferred) or M.S. with 2-4 years of relevant industry or academic experience.
- Strong understanding of current DNA assembly approaches, including Gibson, Golden Gate, round the horn site directed mutagenesis etc.
- Design experience using molecular biology software (like Benchling, Geneious Prime 2) for DNA constructs.
- Previous experience of handling plasmids for Lentivirus, AAV and associated techniques.
- Hands on experience with genome editing technologies like CRISPR/Cas9, TALEN, transposons etc.
- Experience in laboratory automation and liquid handling like use of Hamilton, Bravo, QPix is a plus.
- Knowledge and experience in NGS related genomic technologies desired by not required.
- Experience in mammalian cell culture, transfection is a plus.
- Attention to detail and problem-solving skills.
- Motivated, curious, and comfortable working with highly technical projects and personnel.
- Excellent communication and presentation skills, capable of conveying technical information in a clear and thorough manner.
- Comfortable delivering against challenging commitments.
- Demonstrated ability to thrive working with highly skilled teams in a fast-paced, entrepreneurial and technical environment.
More About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $50B in aggregate value. To date, Flagship has deployed over $2.2B in capital toward the founding and growth of its pioneering companies alongside more than $18B of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).